| 1 |
中华医学会儿科学分会新生儿学组，《中华儿科杂志》编辑委员会. 新生儿肺动脉高压诊治专家共识 [J]. 中华儿科杂志, 2017, 55(3):163.
|
| 2 |
Steurer MA, Jelliffe-Pawlowski LL, Baer RJ, et al. Persistent pulmonary hypertension of the newborn in late preterm and term infants in California [J]. Pediatrics, 2017, 139(1). pii: e20161165.
|
| 3 |
Nakwan N, Jain S, Kumar K, et al. An Asian multicenter retrospective study on persistent pulmonary hypertension of the newborn: incidence, etiology, diagnosis, treatment and outcome [J]. J Matern Fetal Neonatal Med, 2018, 14: 1-11.
|
| 4 |
Delaney C, Cornfield DN. Risk factors for persistent pulmonary hypertension of the newborn [J]. Pulm Circ, 2012, 2(1): 15-20.
|
| 5 |
Sharma V, Berkelhamer S, Lakshminrusimha S. Persistent pulmonary hypertension of the newborn [J]. Matern Health Neonatol Perinatol, 2015, 1: 14.
|
| 6 |
Ivy DD, Abman SH, Barst RJ, et al. Pediatric pulmonary hypertension [J]. J Am Coll Cardiol, 2013, 62(25 Suppl): D117-126.
|
| 7 |
Steinhorn RH. Advances in neonatal pulmonary hypertension [J]. Neonatology, 2016, 109(4): 334-344.
|
| 8 |
Mathew B, Lakshminrusimha S. Persistent pulmonary hypertension in the newborn [J]. Children (Basel), 2017, 4(8). pii: E63.
|
| 9 |
Jain A, Mcnamara PJ. Persistent pulmonary hypertension of the newborn: Advances in diagnosis and treatment [J]. Semin Fetal Neonatal Med, 2015, 20(4): 262-271.
|
| 10 |
Fuloria M, Aschner JL. Persistent pulmonary hypertension of the newborn [J]. Semin Fetal Neonatal Med, 2017, 22(4): 220-226.
|
| 11 |
Vijlbrief DC, Benders MJ, Kemperman H, et al. B-type natriuretic peptide and rebound during treatment for persistent pulmonary hypertension [J]. J Pediatr, 2012, 160(1): 111-5.e1.
|
| 12 |
Lakshminrusimha S, Keszler M. Persistent pulmonary hypertension of the newborn [J]. Neoreviews, 2015, 16(12): e680-e692.
|
| 13 |
Nair J, Lakshminrusimha S. Update on PPHN: mechanisms and treatment [J]. Semin Perinatol, 2014, 38(2): 78-91.
|
| 14 |
Wung JT, James LS, Kilchevsky E, et al. Management of infants with severe respiratory failure and persistence of the fetal circulation, without hyperventilation [J]. Pediatrics, 1985, 76(4): 488-494.
|
| 15 |
Luecke C, Mcpherson C. Treatment of persistent pulmonary hypertension of the newborn: Use of pulmonary vasodilators in term neonates [J]. Neonatal Netw, 2017, 36(3): 160-168.
|
| 16 |
Lakshminrusimha S, Russell JA, Steinhorn RH, et al. Pulmonary hemodynamics in neonatal lambs resuscitated with 21%, 50%, and 100% oxygen [J]. Pediatr Res, 2007, 62(3): 313-318.
|
| 17 |
Farrow KN, Groh BS, Schumacker PT, et al. Hyperoxia increases phosphodiesterase 5 expression and activity in ovine fetal pulmonary artery smooth muscle cells [J]. Circ Res, 2008, 102(2): 226-233.
|
| 18 |
Farrow KN, Lakshminrusimha S, Czech L, et al. SOD and inhaled nitric oxide normalize phosphodiesterase 5 expression and activity in neonatal lambs with persistent pulmonary hypertension [J]. Am J Physiol Lung Cell Mol Physiol, 2010, 299(1): L109-116.
|
| 19 |
Lazar DA, Cass DL, Olutoye OO, et al. The use of ECMO for persistent pulmonary hypertension of the newborn: a decade of experience [J]. J Surg Res, 2012, 177(2): 263-267.
|
| 20 |
Kinsella JP. Inhaled nitric oxide in the term newborn [J]. Early Hum Dev, 2008, 84(11): 709-716.
|
| 21 |
Diblasi RM, Myers TR, Hess DR. Evidence-based clinical practice guideline: inhaled nitric oxide for neonates with acute hypoxic respiratory failure [J]. Respir Care, 2010, 55(12): 1717-1745.
|
| 22 |
Tanriverdi S, Koroglu OA, Uygur O, et al. The effect of inhaled nitric oxide therapy on thromboelastogram in newborns with persistent pulmonary hypertension [J]. Eur J Pediatr, 2014, 173(10): 1381-1385.
|
| 23 |
More K, Athalye-Jape GK, Rao SC, et al. Endothelin receptor antagonists for persistent pulmonary hypertension in term and late preterm infants [J]. Cochrane Database Syst Rev, 2016, (8): CD010531.
|
| 24 |
Maiya S, Hislop AA, Flynn Y, et al. Response to bosentan in children with pulmonary hypertension [J]. Heart, 2006, 92(5): 664-670.
|
| 25 |
Steinhorn RH, Fineman J, Kusic-Pajic A, et al. Bosentan as adjunctive therapy for persistent pulmonary hypertension of the newborn: results of the randomized multicenter placebo-controlled exploratory trial [J]. J Pediatr, 2016, 177: 90-96.e3.
|
| 26 |
Eronen M, Pohjavuori M, Andersson S, et al. Prostacyclin treatment for persistent pulmonary hypertension of the newborn [J]. Pediatr Cardiol, 1997, 18(1): 3-7.
|
| 27 |
Ivy DD, Claussen L, Doran A. Transition of stable pediatric patients with pulmonary arterial hypertension from intravenous epoprostenol to intravenous treprostinil [J]. Am J Cardiol, 2007, 99(5): 696-698.
|
| 28 |
Park BY, Chung SH. Treprostinil for persistent pulmonary hypertension of the newborn, with early onset sepsis in preterm infant: 2 Case reports [J]. Medicine (Baltimore), 2017, 96(26): e7303.
|
| 29 |
Kelly LK, Porta NF, Goodman DM, et al. Inhaled prostacyclin for term infants with persistent pulmonary hypertension refractory to inhaled nitric oxide [J]. J Pediatr, 2002, 141(6): 830-832.
|
| 30 |
Yilmaz O, Kahveci H, Zeybek C, et al. Inhaled iloprost in preterm infants with severe respiratory distress syndrome and pulmonary hypertension [J]. Am J Perinatol, 2014, 31(4): 321-326.
|
| 31 |
Murray F, Maclean MR, Pyne NJ. Increased expression of the cGMP-inhibited cAMP-specific (PDE3) and cGMP binding cGMP-specific (PDE5) phosphodiesterases in models of pulmonary hypertension [J]. Br J Pharmacol, 2002, 137(8): 1187-1194.
|
| 32 |
Page CP. Phosphodiesterase inhibitors for the treatment of asthma and chronic obstructive pulmonary disease [J]. Int Arch Allergy Immunol, 2014, 165(3): 152-164.
|
| 33 |
Yan Y, Jiang W, Liu J, et al. Expression of recombinant phosphodiesterases 3A and 3B using baculovirus expression system [J]. Iran J Biotechnol, 2016, 14(4): 236-242.
|
| 34 |
Fraisse A, Wessel DL. Acute pulmonary hypertension in infants and children: cGMP-related drugs [J]. Pediatr Crit Care Med, 2010, 11(2 Suppl): S37-40.
|
| 35 |
Shah PS, Ohlsson A. Sildenafil for pulmonary hypertension in neonates [J]. Cochrane Database Syst Rev, 2011, (8): CD005494.
|
| 36 |
Dhariwal AK, Bavdekar SB. Sildenafil in pediatric pulmonary arterial hypertension [J]. J Postgrad Med, 2015, 61(3): 181-192.
|
| 37 |
FDA. FDA Drug Safety Communication: FDA recommends against use of Revatio (sildenafil) in children with pulmonary hypertension [EB/OL]. 2012.
URL
|
| 38 |
Tessler RB, Zadinello M, Fiori H, et al. Tadalafil improves oxygenation in a model of newborn pulmonary hypertension [J]. Pediatr Crit Care Med, 2008, 9(3): 330-332.
|